Whisker’s Litter-Robot Becomes the First Automatic Litter Box Eligible for HSA/FSA Spending
The milestone expands access to barrier-reducing cat care and builds on Whisker's mission to simplify pet parenting through thoughtful, intelligent...
Staff
Expion Health Announces Qlare™, a Breakthrough Conversational AI Tool Transforming Prescription Cost Decision-Making
NORTH BETHESDA, Md., Dec. 5, 2025 /PRNewswire/ -- Expion Health announced today the upcoming launch of Qlare™, a major advancement to...
November in Review: 10 Top Health Press Releases
A roundup of the most newsworthy healthcare press releases from PR Newswire, including new company mergers, Alzheimer's fundraising and advances...
Exousia Pro, Inc. Revolutionizes Nutraceuticals With Launch Of Maxasome(TM): The First All-Natural, Biologically Active Exosomal Supplement
ORLANDO, FLORIDA / ACCESS Newswire / December 5, 2025 / Exousia Pro, Inc. (OTCID:MAJI), a clinical-stage biotechnology company leveraging proprietary...
Medical Care Technologies Inc. (OTC Pink:MDCE) Closes Reg A – Dilution Ends, Growth Phase Begins
MESA, ARIZONA / ACCESS Newswire / December 5, 2025 / Medical Care Technologies Inc. (OTC Pink:MDCE) is pleased to announce...
Owlet Launches TGA-Approved Dream Sock™ in Australia & New Zealand, Expanding International Footprint and Bringing Trusted Pediatric Health Monitoring to More Families Worldwide
TGA approval enables regional launch of Owlet’s clinically validated, award-winning infant health monitor; Owlet360™ subscription marks first international expansion of...
CONMED Corporation Announces Strategic Exit from Gastroenterology Product Lines
Concludes Distribution Agreement with Gore® for VIABIL® in the United States and Canada, Effective January 1, 2026 Announces Intent to...
TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease on December 15, 2025
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with...
Accendatech US comments on the recent setback in phase 2 study to evaluate STAT3 as therapeutic target and other drug development strategies such as AI and precision medicine to treat patients with IPF
BOSTON, Dec. 05, 2025 (GLOBE NEWSWIRE) -- A recent setback due to unexpected safety concern from a phase 2 study...
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
—Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs)...
Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025
Monthly reductions in seizure frequency of 90.9% among participants treated for ≥48 months in the OLE, with 38% achieving ≥1...
XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc
EMERYVILLE, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA), the biotech royalty aggregator, today...
Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures
Post-hoc analysis of RAP-219 Phase 2a data showed early onset of action and consistency of median response over the entire...
Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad
NEW YORK, Dec. 05, 2025 (GLOBE NEWSWIRE) -- via BioMedWire: — Soligenix Inc. (NASDAQ: SNGX) today announces its placement in...
Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum
THE WOODLANDS, Texas, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced clinical data on adipose tissue...
New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer
Cretostimogene demonstrated HG-EFS at 3- 6- and 9-months of 95.7%, 84.6% and 80.4%, respectively, in HR BCG UR Ta/T1 Disease...
GeneLife Expands GeneAI Forecast With New Cancer Risk Prediction Models
AI-Driven Risk Prediction for Breast, Prostate and Pancreatic CancersTOKYO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- A.D.A.M. Innovations Co. (Japanese Name:...
Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson’s Disease
Interim data show substantial improvements in “Good On” time compared to other oral CD/LD therapiesCREXONT delivered substantial “Off” time reductions,...
Avantor® Appoints Sanjeev Mehra to its Board of Directors
RADNOR, Pa., Dec. 4, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services...
Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement
Extends cash runway into first half of 2028, beyond planned completion of ViraxImmune™ US based regulatory study in post-acute sequelae of...